{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T17:11:08Z","timestamp":1794157868386,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) is a global health problem associated with significant morbidity during reproductive age. Only a few published studies that address the clinical manifestations and phenotypic presentation of the disease have been conducted in Africa, including Sudan. Thus, this study aimed to evaluate the clinical and biochemical presentation of the different PCOS phenotypes among infertile Sudanese women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional, descriptive study was conducted from January to December 2019. A total of 368 infertile women with PCOS (based on the Rotterdam criteria) were recruited from a fertility center in Khartoum, Sudan. Clinical, hormonal, and ultrasonographic characteristics were described and compared between the four phenotypes of PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Majority (321 [87.2%]) of the women had oligo\/anovulation (OA). Polycystic ovary morphology on ultrasound appeared in 236 (64.1%) women, acne in 171 (46.5%) women, acanthosis nigricans in 81 (22.0%) women, and hirsutism in 101 (27.4%) women. Phenotype D was the most prevalent among infertile Sudanese women (51.6%), followed by phenotype B (22.6%), phenotype C (18.2%), and phenotype A (7.6%). No statistical differences in the body mass index and hormonal profile between the four phenotypes were noted. Women with phenotype A were older and had high mean blood pressure, and a higher waist\/hip ratio was observed among women with phenotype D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Unlike the global distribution of PCOS phenotypes, Sudanese women uniquely expressed phenotype D as the most prevalent. More epidemiological studies are needed in the region due to geographical, ethnic, and genetic variations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-022-01762-6","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T07:09:48Z","timestamp":1652425788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Alawia N.","family":"Elasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel B. A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal E.","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Abusham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaeldin","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishag","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"1762_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09513590.2018.1488958","volume":"35","author":"M Ntumy","year":"2019","unstructured":"Ntumy M, Maya E, Lizneva D, Adanu R, Azziz R. The pressing need for standardization in epidemiologic studies of PCOS across the globe. Gynecol Endocrinol. 2019;35:1\u20133.","journal-title":"Gynecol Endocrinol"},{"key":"1762_CR2","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31:2841\u201355.","journal-title":"Hum Reprod"},{"key":"1762_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.15171\/jcvtr.2018.10","volume":"10","author":"J Hallajzadeh","year":"2018","unstructured":"Hallajzadeh J, Khoramdad M, Karamzad N, Almasi-Hashiani A, Janati A, Ayubi E, et al. Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis. J Cardiovasc Thorac Res. 2018;10:56\u201369.","journal-title":"J Cardiovasc Thorac Res"},{"key":"1762_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12916-020-01861-x","volume":"18","author":"CT Tay","year":"2020","unstructured":"Tay CT, Hart RJ, Hickey M, Moran LJ, Earnest A, Doherty DA, et al. Updated adolescent diagnostic criteria for polycystic ovary syndrome: impact on prevalence and longitudinal body mass index trajectories from birth to adulthood. BMC Med. 2020;18:389.","journal-title":"BMC Med"},{"key":"1762_CR5","doi-asserted-by":"publisher","first-page":"6306410","DOI":"10.1155\/2016\/6306410","volume":"2016","author":"AS Lagan\u00e0","year":"2016","unstructured":"Lagan\u00e0 AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, et al. Metabolism and ovarian function in PCOS women: a therapeutic approach with inositols. Int J Endocrinol. 2016;2016:6306410. https:\/\/doi.org\/10.1155\/2016\/6306410.","journal-title":"Int J Endocrinol"},{"key":"1762_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/09513590.2016.1144741","volume":"32","author":"C Paul","year":"2016","unstructured":"Paul C, Lagan\u00e0 AS, Maniglio P, Triolo O, Brady DM. Inositol\u2019s and other nutraceuticals\u2019 synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecol Endocrinol. 2016;32:431\u20138. https:\/\/doi.org\/10.3109\/09513590.2016.1144741.","journal-title":"Gynecol Endocrinol"},{"issue":"19","key":"1762_CR7","first-page":"41","volume":"2004","author":"BCJM Fauser","year":"2003","unstructured":"Fauser BCJM, Tarlatzis F, Chang A, Legro R, et al. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2003;2004(19):41\u20137.","journal-title":"Hum Reprod"},{"key":"1762_CR8","unstructured":"Evidence-based Methodology Workshop on Polycystic Ovary Syndrome (PCOS) | NIH Office of Disease Prevention Website https:\/\/prevention.nih.gov\/research-priorities\/research-needs-and-gaps\/pathways-prevention\/evidence-based-methodology-workshop-polycystic-ovary-syndrome-pcos. Accessed 28 Apr 2022."},{"key":"1762_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","volume":"33","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602\u201318.","journal-title":"Hum Reprod"},{"key":"1762_CR10","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.12659\/MSM.909715","volume":"24","author":"H Zhao","year":"2018","unstructured":"Zhao H, Song X, Zhang L, Xu Y, Wang X. Comparison of androgen levels, endocrine and metabolic indices, and clinical findings in women with polycystic ovary syndrome in uygur and han ethnic groups from Xinjiang province in China. Med Sci Monit. 2018;24:6774\u201380.","journal-title":"Med Sci Monit"},{"key":"1762_CR11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.fertnstert.2016.07.1121","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016;106:1510-1520.e2.","journal-title":"Fertil Steril"},{"key":"1762_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coemr.2020.03.004","volume":"12","author":"S Mumusoglu","year":"2020","unstructured":"Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: differential impact of diagnostic criteria and clinical versus unselected population. Curr Opin Endocrine Metab Res. 2020;12:66\u201371.","journal-title":"Curr Opin Endocrine Metab Res"},{"key":"1762_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ypmed.2007.08.012","volume":"45","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (Baltim). 2007;45:247\u201351.","journal-title":"Prev Med (Baltim)"},{"key":"1762_CR14","first-page":"763","volume":"16","author":"F Mehrabian","year":"2011","unstructured":"Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci. 2011;16:763\u20139.","journal-title":"J Res Med Sci"},{"key":"1762_CR15","unstructured":"NCDs | STEPwise approach to surveillance (STEPS). WHO. 2020. https:\/\/www.who.int\/teams\/noncommunicable-diseases\/surveillance\/systems-tools\/steps. Accessed 28 Apr 2022."},{"key":"1762_CR16","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/jog.14097","volume":"45","author":"NT Cao","year":"2019","unstructured":"Cao NT, Le MT, Nguyen VQH, Pilgrim J, Le VNS, Le DD, et al. Defining polycystic ovary syndrome phenotype in Vietnamese women. J Obstet Gynaecol Res. 2019;45:2209\u201319.","journal-title":"J Obstet Gynaecol Res"},{"key":"1762_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2471\/BLT.10.077982","volume":"89","author":"O Erika","year":"2011","unstructured":"Erika O, Megumi H, Motoi S, Dang DA, Le HT, Nguyen TTT, et al. Maternal body mass index and gestational weight gain and their association with perinatal outcomes in Viet Nam. Bull World Heal Organ. 2011;89:127\u201336.","journal-title":"Bull World Heal Organ"},{"key":"1762_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5468\/ogs.2017.60.2.187","volume":"60","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Awooda HA, Rayis DA, Hamdan HZ, Adam I, Lutfi MF. Thyroid function\/antibodies in sudanese women with polycystic ovarian disease. Obs Gynecol Sci. 2017;60:187\u201392.","journal-title":"Obs Gynecol Sci"},{"issue":"6","key":"1762_CR19","doi-asserted-by":"publisher","first-page":"E1088","DOI":"10.1210\/jc.2013-1295","volume":"98","author":"U Ezeh","year":"2013","unstructured":"Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(6):E1088\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"1762_CR20","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/s41598-017-05717-y","volume":"7","author":"M Al-Jefout","year":"2017","unstructured":"Al-Jefout M, Alnawaiseh N, Al-Qtaitat A. Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. Sci Rep. 2017;7:5339.","journal-title":"Sci Rep"},{"key":"1762_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/bmj.327.7414.546","volume":"327","author":"DH Fairley","year":"2003","unstructured":"Fairley DH, Taylor A. Anovulation. BMJ. 2003;327:546.","journal-title":"BMJ"},{"key":"1762_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456\u201388.","journal-title":"Fertil Steril"},{"key":"1762_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/humrep\/det469","volume":"29","author":"MP Lauritsen","year":"2014","unstructured":"Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-M\u00fcllerian hormone. Hum Reprod. 2014;29:791\u2013801.","journal-title":"Hum Reprod"},{"key":"1762_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00404-012-2568-z","volume":"287","author":"HY Zhang","year":"2013","unstructured":"Zhang HY, Guo CX, Zhu FF, Qu PP, Lin WJ, Xiong J. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study. Arch Gynecol Obstet. 2013;287:525\u201331.","journal-title":"Arch Gynecol Obstet"},{"key":"1762_CR25","first-page":"175","volume":"11","author":"AB Pembe","year":"2009","unstructured":"Pembe AB, Abeid MS. Polycystic ovaries and associated clinical and biochemical features among women with infertility in a tertiary hospital in Tanzania. Tanzan J Health Res. 2009;11:175\u201380.","journal-title":"Tanzan J Health Res"},{"key":"1762_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00404-015-3889-5","volume":"293","author":"AS Jamil","year":"2016","unstructured":"Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293:447\u201356.","journal-title":"Arch Gynecol Obstet"},{"key":"1762_CR27","first-page":"313","volume":"22","author":"GO Ugwu","year":"2013","unstructured":"Ugwu GO, Iyoke CA, Onah HE, Mba SG. Prevalence, presentation and management of polycystic ovary syndrome in Enugu, south east Nigeria. Niger J Med. 2013;22:313\u20136.","journal-title":"Niger J Med"},{"key":"1762_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijgo.2013.09.025","volume":"125","author":"AS Sanad","year":"2014","unstructured":"Sanad AS. Prevalence of polycystic ovary syndrome among fertile and infertile women in Minia Governorate. Egypt Int J Gynecol Obstet. 2014;125:81\u20132.","journal-title":"Egypt Int J Gynecol Obstet"},{"key":"1762_CR29","doi-asserted-by":"crossref","unstructured":"Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. In: Fertility and Sterility. Elsevier Inc.; 2012. p. 28\u201338.e25.","DOI":"10.1016\/j.fertnstert.2011.09.024"},{"key":"1762_CR30","doi-asserted-by":"crossref","unstructured":"Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab. 2010; 2038\u201349.","DOI":"10.1210\/jc.2009-2724"},{"key":"1762_CR31","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/humrep\/det262","volume":"28","author":"R Li","year":"2013","unstructured":"Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28:2562\u20139.","journal-title":"Hum Reprod"},{"key":"1762_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000277640","volume":"69","author":"C Moran","year":"2010","unstructured":"Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest. 2010;69:274\u201380.","journal-title":"Gynecol Obstet Invest"},{"key":"1762_CR33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11906-014-0500-6","volume":"16","author":"M Luque-Ram\u00edrez","year":"2014","unstructured":"Luque-Ram\u00edrez M, Escobar-Morreale HF. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity. Curr Hypertens Rep. 2014;16:500.","journal-title":"Curr Hypertens Rep"},{"key":"1762_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejogrb.2013.05.019","volume":"170","author":"S Sahmay","year":"2013","unstructured":"Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H. Serum anti-mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;170:157\u201361.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1762_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1530\/EC-19-0496","volume":"9","author":"SF de Medeiros","year":"2020","unstructured":"de Medeiros SF, Yamamoto MMW, de Medeiros MAS, Barbosa BB, Soares JM, Baracat EC. Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age. Endocr Connect. 2020;9:74\u201389.","journal-title":"Endocr Connect"},{"key":"1762_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","volume":"132","author":"R Azziz","year":"2018","unstructured":"Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132:321\u201336.","journal-title":"Obstet Gynecol"},{"key":"1762_CR37","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1471-0528.2009.02347.x","volume":"116","author":"HY Zhang","year":"2009","unstructured":"Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG Int J Obstet Gynaecol. 2009;116:1633\u20139.","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"1762_CR38","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1055\/s-0031-1277136","volume":"119","author":"S Cupisti","year":"2011","unstructured":"Cupisti S, Haeberle L, Schell C, Richter H, Schulze C, Hildebrandt T, et al. The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids. Exp Clin Endocrinol Diabetes. 2011;119:502\u20138.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1762_CR39","first-page":"160","volume":"18","author":"O Ogueh","year":"2014","unstructured":"Ogueh O, Zini M, Williams S, Ighere J. The prevalence of polycystic ovary morphology among women attending a new teaching hospital in southern Nigeria. Afr J Reprod Health. 2014;18:160\u20133.","journal-title":"Afr J Reprod Health"},{"key":"1762_CR40","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.fertnstert.2006.11.012","volume":"87","author":"LA Wise","year":"2007","unstructured":"Wise LA, Palmer JR, Stewart EA, Rosenberg L. Polycystic ovary syndrome and risk of uterine leiomyomata. Fertil Steril. 2007;87:1108\u201315.","journal-title":"Fertil Steril"},{"key":"1762_CR41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/J.TEM.2020.04.003","volume":"31","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Espinola MSB, Dewailly D, Ozay AC, Prapas N, Vazquez-Levin M, et al. Breakthroughs in the use of inositols for assisted reproductive treatment (ART). Trends Endocrinol Metab. 2020;31:570\u20139. https:\/\/doi.org\/10.1016\/J.TEM.2020.04.003.","journal-title":"Trends Endocrinol Metab"},{"key":"1762_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/S00404-018-4861-Y","volume":"298","author":"AS Lagan\u00e0","year":"2018","unstructured":"Lagan\u00e0 AS, Vitagliano A, Noventa M, Ambrosini G, D\u2019Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;298:675\u201384. https:\/\/doi.org\/10.1007\/S00404-018-4861-Y.","journal-title":"Arch Gynecol Obstet"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01762-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T07:10:58Z","timestamp":1652425858000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01762-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01762-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"11 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research and Ethical Committee of the Department of Obstetrics and Gynecology, Faculty of Medicine, University of Khartoum, Sudan (#2018, 11). Informed consents were signed by the participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}